{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T21:09:41Z","timestamp":1791061781318,"version":"4.1.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1097\/01.ftd.0000175911.70172.2e","type":"journal-article","created":{"date-parts":[[2005,9,20]],"date-time":"2005-09-20T04:01:51Z","timestamp":1127188911000},"page":"666-676","source":"Crossref","is-referenced-by-count":70,"title":["The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation"],"prefix":"10.1097","volume":"27","author":[{"given":"Vincent H","family":"Mabasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary H. H","family":"Ensom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20-20210129","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/S0041-1345(01)02369-7","article-title":"The role of Certican in the many pathways of chronic rejection.","volume":"33","author":"Nashan","year":"2001","journal-title":"Transplant Proc"},{"key":"R5-20-20210129","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00007890-199707150-00008","article-title":"SDZ RAD a new rapamycin derivative: pharmacological properties in vitro and in vivo.","volume":"64","author":"Schuler","year":"1997","journal-title":"Transplantation"},{"key":"R6-20-20210129","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus.","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R7-20-20210129","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1067\/mcp.2001.112969","article-title":"Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine.","volume":"69","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20-20210129","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1046\/j.1365-2125.1999.00085.x","article-title":"Entry into human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.","volume":"48","author":"Neumayer","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20-20210129","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2165\/00003088-199834040-00001","article-title":"Clinical pharmacokinetics in the 21st century: does the evidence support definitive outcomes?","volume":"34","author":"Ensom","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"R10-20-20210129","doi-asserted-by":"crossref","first-page":"11532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus 12 month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients.","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"R11-20-20210129","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1097\/00007890-200105270-00008","article-title":"RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection.","volume":"71","author":"Kahan","year":"2001","journal-title":"Transplantation"},{"key":"R12-20-20210129","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1097\/01.TP.0000140486.97461.49","article-title":"Everolimus and reduced-exposure cyclosporine in de novo renal transplant recipients: a three year phase II, randomized, multicenter, open label study.","volume":"78","author":"Nashan","year":"2004","journal-title":"Transplantation"},{"key":"R13-20-20210129","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1600-6143.2004.00389.x","article-title":"Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies.","volume":"4","author":"Vitko","year":"2004","journal-title":"Am J Transplant"},{"key":"R14-20-20210129","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1056\/NEJMoa022171","article-title":"Everolimus for the prevention of allograft rejection and vasculopathy in cardiac transplant recipients.","volume":"349","author":"Eisen","year":"2003","journal-title":"N Engl J Med"},{"key":"R15-20-20210129","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S1053-2498(02)01221-4","article-title":"Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure.","volume":"22","author":"Kovarik","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"R16-20-20210129","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1097\/01.TP.0000070139.63068.54","article-title":"Everolimus in pediatric de novo renal transplant patients.","volume":"75","author":"Hoyer","year":"2003","journal-title":"Transplantation"},{"key":"R17-20-20210129","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/S0041-1345(02)03204-9","article-title":"Everolimus in combination with neural in pediatric renal transplant recipients: interim analysis after 3 months.","volume":"34","author":"Vester","year":"2002","journal-title":"Transplant Proc"},{"key":"R18-20-20210129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1570-0232(02)00107-1","article-title":"Quantification and stability of everolimus in human blood by high-performance liquid chromatography-electrospray tandem mass spectrometry.","volume":"772","author":"Salm","year":"2002","journal-title":"J Chromatogr B"},{"key":"R19-20-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jchromb.2004.11.016","article-title":"High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus.","volume":"816","author":"Baldelli","year":"2005","journal-title":"J Chromatogr B"},{"key":"R20-20-20210129","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1515\/CCLM.2002.045","article-title":"Simultaneous-quantification of sirolimus, everolimus, tacrolimus and cyclosporine by liquid-chromatography-mass spectrometry.","volume":"40","author":"Deters","year":"2002","journal-title":"Clin Chem Lab Med"},{"key":"R21-20-20210129","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/1097-0231(20001115)14:21<1965::AID-RCM118>3.0.CO;2-0","article-title":"High throughput analysis of everolimus and cyclosporin A in whole blood by liquid chromatography\/mass spectrometry using a semi-automated 96-well solid-phase extraction system.","volume":"14","author":"McMahon","year":"2000","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R22-20-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0378-4347(00)00380-7","article-title":"Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants.","volume":"748","author":"Christians","year":"2000","journal-title":"J Chromatogr B"},{"key":"R23-20-20210129","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/clinchem\/44.6.1275","article-title":"Automated simultaneous quantification of the immunosuppressants 40-O-(2-hydroxyethyl) rapamycin and cyclosporine in blood with electrospray-mass spectrometric detection.","volume":"44","author":"Vidal","year":"1998","journal-title":"Clin Chem"},{"key":"R24-20-20210129","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/clinchem\/48.6.955","article-title":"Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood.","volume":"48","author":"Streit","year":"2002","journal-title":"Clin Chem"},{"key":"R25-20-20210129","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0378-4347(98)00426-5","article-title":"Development of a high performance liquid chromatographic-electrospray mass spectrometric assay for the specific and sensitive quantification of the novel immunosuppressive macrolide 40-O-(2-hydroxyethyl) rapamycin.","volume":"720","author":"Segarra","year":"1998","journal-title":"J Chromatogr B"},{"key":"R26-20-20210129","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/rcm.323","article-title":"High throughput semi-automated 96-well liquid\/liquid extraction and liquid chromatography\/mass spectrometric analysis of everolimus and cyclosporine A in whole blood.","volume":"15","author":"Brignol","year":"2001","journal-title":"Rapid Commun Mass Spectrom"},{"key":"R27-20-20210129","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/00007691-199702000-00022","article-title":"Determination of rapamycin in whole blood by HPLC.","volume":"19","author":"Svensson","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R28-20-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/01.ftd.0000152681.13647.85","article-title":"Validation of a practical liquid chromatography with ultraviolet detection method for quantification of whole-blood everolimus in clinical TDM laboratory.","volume":"27","author":"Boudennaia","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R29-20-20210129","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00007691-200504000-00140","article-title":"Cross-reactivity of the major everolimus hydroxy metabolites with the Innofluor Certican immunoassay for clinical TDM of everolimus [abstract].","volume":"27","author":"Strom","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R30-20-20210129","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/00007691-200504000-00043","article-title":"Comparison of the Seradyn Innofluor Certican assay on TDXFLX system with LC\/MS-MS [abstract].","volume":"27","author":"Engelmayer","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R31-20-20210129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00007691-200410000-00007","article-title":"Everolimus therapeutic concentration range defined from a prospective trial with reduced exposure cyclosporin in de novo kidney transplantation.","volume":"26","author":"Kovarik","year":"2004","journal-title":"Ther Drug Monit"},{"key":"R32-20-20210129","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2165\/00019053-200220100-00004","article-title":"Mycophenolate mofetil: a pharmacoeconomic review of its use in solid organ transplant.","volume":"20","author":"Young","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"R33-20-20210129","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1432-2277.2004.tb00426.x","article-title":"Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients.","volume":"17","author":"Holmes","year":"2004","journal-title":"Transpl Int"},{"key":"R34-20-20210129","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1067\/mcp.2001.118022","article-title":"Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications.","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R35-20-20210129","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0009-9236(01)15633-X","article-title":"Influence of hepatic impairment on everolimus pharmacokinetics: Implications for dose adjustment.","volume":"70","author":"Kovarik","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"R36-20-20210129","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1046\/j.1600-6143.2004.00601.x","article-title":"Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling.","volume":"4","author":"Starling","year":"2004","journal-title":"Am J Transplant"},{"key":"R37-20-20210129","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-200203270-00016","article-title":"Exposure-relationships for everolimus in de novo kidney transplantation.","volume":"73","author":"Kovarik","year":"2002","journal-title":"Transplantation"},{"key":"R38-20-20210129","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/00007890-200101150-00028","article-title":"Pharmacokinetics and tolerability of 40-O-[2-hydroxyethyl] rapamycin in de novo liver transplant recipients.","volume":"71","author":"Levy","year":"2001","journal-title":"Transplantation"},{"key":"R39-20-20210129","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1097\/00007890-199910270-00007","article-title":"A phase I study of a 4-week course of SDZ RAD in quiescent cyclosporine-prednisone-treated renal transplant recipients.","volume":"68","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"R40-20-20210129","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.amjcard.2004.08.074","article-title":"Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).","volume":"95","author":"Costa","year":"2005","journal-title":"Am J Cardiol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.ftd.0000175911.70172.2e","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:59:55Z","timestamp":1785855595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007691-200510000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.ftd.0000175911.70172.2e","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}